Photo taken from Erman Akkus/X
Apr 2, 2024, 05:45
Erman Akkus: Is adjuvant Gem-Cis better than capecitabine in operated node-positive extrahepatic cholangiocarcinoma?
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“Is adjuvant Gem-Cis better than capecitabine in operated node-positive extrahepatic cholangiocarcinoma? STAMP trial: Not a negative study.
- 101 patients
- 31.7% had R1 resection
- 2-year disease-free survival: 38.5% vs 25.1% (HR=0.96 (CI, 0.71–1.30), p=0.430)
- median overall survival: 35.7 mo (29.5–NE) vs 35.7 months (30.9–NE) [HR=1.08 (CI, 0.71–1.64), 1-sided p=0.404)
- Grade 3–4 AE: 84% vs 16%”
Read further.
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43
Nov 12, 2024, 19:34